Cyclosporine Market Report 2025 (Global Edition)

Global Cyclosporine Market Report 2024 Market Size Split by Route of Administration Outlook: (Oral, Injectable, Topical), by Indication Outlook: (Transplant Rejection Prophylaxis, Rheumatoid Arthritis...

Cyclosporine Market Report Description

We have various report editions of Cyclosporine Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.

Competitive Landscape of the Cyclosporine Market

The Cyclosporine market is highly competitive, with major players focusing on product innovation, generic formulations, and strategic partnerships to strengthen their market presence. Increasing competition among regional and global manufacturers is driving advancements in cost-effective production and expanded distribution networks.

In August 2024, AbbVie completed its acquisition of Cerevel Therapeutics, integrating the company into its portfolio. AbbVie CEO Robert A. Michael expressed excitement about the acquisition, noting it strengthens their neuroscience division and aligns with their commitment to improving patient outcomes in neurological and psychiatric conditions. (Source: https://news.abbvie.com/2024-08-01-AbbVie-Completes-Acquisition-of-Cerevel-Therapeutics) In December 2024, Hikma Pharmaceuticals PLC, a global pharmaceutical company, received FDA approval and launched its generic version of Victoza® (Liraglutide Injection) in a 6 mg/mL dosage in the United States. Liraglutide Injection, a GLP-1 receptor agonist, is indicated as an adjunct to diet and exercise for improving glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus. (Source: https://www.hikma.com/news/hikma-receives-fda-approval-and-launches-the-generic-version-of-victoza-liraglutide-in-the-us/) In December 2024, Teva Pharmaceutical Industries Ltd. announced an agreement with JKI, a company established by a fund managed and operated by J-Will. Under this agreement, all shares of Teva Takeda Pharma Limited and its wholly owned subsidiary, Teva Takeda Yakuhin Ltd., will be transferred to JKI. (Source: https://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2024/Teva-Announces-Agreement-to-Divest-Teva-Takeda-its-Business-Venture-in-Japan/default.aspx)

Top Companies Market Share in Cyclosporine Industry: (In no particular order of Rank)

• Novartis AG
• AbbVie Inc.
• Hikma Pharmaceuticals PLC
• Teva Pharmaceutical Industries Ltd.
• Mylan N.V.
• Roche Holding AG
• Sun Pharmaceutical Industries Ltd.
• Astellas Pharma Inc.
• Sandoz (a Novartis division)
• Zydus Cadila
• Confidential Data
• Access The Paid Version
• Data Hidden

*List of Second Tier Companies, List of Third Tier/ Start-up Companies (Inquire with sales executive) Request Any Company Profile for Preview Purpose OR Data Validation!

If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.

Regional Analysis of the Cyclosporine Market

Which Region Dominates the Cyclosporine Market in 2024?

According to Cognitive Market Research, North America dominates the Cyclosporine market, driven by a high number of organ transplant procedures, widespread healthcare access, and advanced medical infrastructure. The region benefits from a strong presence of key pharmaceutical players and a well-established healthcare system.

Which Region is Expanding at the Fastest CAGR?

Europe is the fastest-growing region in the Cyclosporine market, fueled by increasing healthcare access and advancements in transplant surgery techniques. The demand for immunosuppressive therapies is rising due to the growing prevalence of autoimmune diseases and ageing populations. Countries like Germany, the UK, and France are key contributors to the market's expansion, driven by strong healthcare infrastructure and evolving treatment guidelines.

The current report Scope analyzes Cyclosporine Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com

• North America (United States, Canada, Mexico)
• Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Netherlands, Switzerland, Belgium)
• Asia-Pacific (China, Japan, Korea, India, Australia, Philippines, Singapore, Malaysia, Thailand, Indonesia, Rest of APAC)
• South America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
• Middle East and Africa (Saudi Arabia, Turkey, Nigeria, UAE, Egypt, South Africa, GCC Countries, Rest of MEA)

The above graph is for illustrative purposes only.

North America Cyclosporine

According to Cognitive Market Research, the global Cyclosporine Market size was estimated at USD 3142.5 Million, out of which North America held the major market share of more than 40% of the global revenue with a market size of USD 1257.00 million in 2024 and will grow at a compound annual growth rate (CAGR) of 13.4% from 2024 to 2031.

• According to Cognitive Market Research, the US had a major share in the Cyclosporine Market with a market size of USD 991.77 million in 2024 and is projected to grow at a CAGR of 13.2% during the forecast period. Dominates due to advanced healthcare infrastructure and the highest number of organ transplants globally.
• The Canada Cyclosporine Market had a market share of USD 150.84 million in 2024 and is projected to grow at a CAGR of 14.2% during the forecast period. Growth was driven by rising awareness of immunosuppressive treatments and strong healthcare access.
• The Mexico Cyclosporine Market is projected to witness growth at a CAGR of 13.9% during the forecast period, with a market size of USD 114.39 million in 2024.

Europe Cyclosporine

According to Cognitive Market Research, the global Cyclosporine Market size was estimated at USD 3142.5 Million, out of which Europe held the market share of more than 30% of the global revenue with a market size of USD 942.75 million in 2024 and will grow at a compound annual growth rate (CAGR) of 13.7% from 2024 to 2031.

• The United Kingdom Cyclosporine Market had a market share of USD 158.38 million in 2024 and is projected to grow at a CAGR of 14.5% during the forecast period. Fastest growing in Europe due to advancements in autoimmune disease treatments and transplant care.
• The France Cyclosporine Market is projected to witness growth at a CAGR of 12.9% during the forecast period, with a market size of USD 86.73 million in 2024.
• According to Cognitive Market Research, the German Cyclosporine Market size was valued at USD 186.66 million in 2024 and is projected to grow at a CAGR of 13.9% during the forecast period. Leads in Europe with its strong pharmaceutical industry and advanced transplant procedures..
• The Italy Cyclosporine Market is projected to witness growth at a CAGR of 13.1% during the forecast period, with a market size of USD 81.08 million in 2024.
• The Russia Cyclosporine Market is projected to witness growth at a CAGR of 12.7% during the forecast period, with a market size of USD 146.13 million in 2024.
• The Spain Cyclosporine Market is projected to witness growth at a CAGR of 12.8% during the forecast period with a market size of USD 77.31 million in 2024
• The Luxembourg Cyclosporine Market is projected to witness growth at a CAGR of 13.8% during the forecast period, with a market size of USD 29.23 million in 2024.
• The Portugal Cyclosporine Market is projected to witness growth at a CAGR of 13.5% during the forecast period, with a market size of USD 19.80 million in 2024.
• The Greece Cyclosporine Market is projected to witness growth at a CAGR of 14.0% during the forecast period, with a market size of USD 11.31 million in 2024.
• The Rest of Europe's Cyclosporine Market is projected to witness growth at a CAGR of 12.4% during the forecast period, with a market size of USD 146.13 million in 2024.

Asia Pacific Cyclosporine

According to Cognitive Market Research, the global Cyclosporine Market size was estimated at USD 3142.5 Million, out of which Asia Pacific held the market share of around 23% of the global revenue with a market size of USD 722.78 million in 2024 and will grow at a compound annual growth rate (CAGR) of 17.2% from 2024 to 2031.

• According to Cognitive Market Research, the China Cyclosporine Market size was valued at USD 325.25 million in 2024 and is projected to grow at a CAGR of 16.7% during the forecast period. Dominates in the Asia Pacific due to its large population and an increasing number of transplant surgeries.
• The Japan Cyclosporine Market is projected to witness growth at a CAGR of 15.7% during the forecast period, with a market size of USD 99.74 million in 2024.
• The India Cyclosporine Market had a market share of USD 86.73 million in 2024 and is projected to grow at a CAGR of 19.0% during the forecast period. It is expanding rapidly with increasing healthcare access and a rising prevalence of autoimmune diseases.
• The South Korean Cyclosporine Market is projected to witness growth at a CAGR of 16.3% during the forecast period, with a market size of USD 72.28 million in 2024.
• The Australian Cyclosporine Market is projected to witness growth at a CAGR of 16.9% during the forecast period, with a market size of USD 37.58 million in 2024.
• The South East Asia Cyclosporine Market is projected to witness growth at a CAGR of 18.2% during the forecast period, with a market size of USD 49.87 million in 2024.
• The Rest of Asia Pacific Cyclosporine Market is projected to witness growth at a CAGR of 17.0% during the forecast period, with a market size of USD 51.32 million in 2024.

South America Cyclosporine

According to Cognitive Market Research, the global Cyclosporine Market size was estimated at USD 3142.5 Million, out of which Latin America held the market share of around 5% of the global revenue with a market size of USD 157.13 million in 2024 and will grow at a compound annual growth rate (CAGR) of 14.6% from 2024 to 2031.

• According to Cognitive Market Research, the Brazil Cyclosporine Market size was valued at USD 67.25 million in 2024 and is projected to grow at a CAGR of 15.2% during the forecast period. Holds dominance in Latin America with improving healthcare systems and the highest regional transplant rates.
• Argentina's Cyclosporine Market had a market share of USD 26.40 million in 2024 and is projected to grow at a CAGR of 15.5% during the forecast period. Growth is fueled by improving healthcare infrastructure and rising disposable incomes.
• Colombia Cyclosporine Market is projected to witness growth at a CAGR of 14.4% during the forecast period, with a market size of USD 13.98 million in 2024.
• Peru Cyclosporine Market is projected to witness growth at a CAGR of 14.8% during the forecast period, with a market size of USD 12.88 million in 2024.
• Chile's Cyclosporine Market is projected to witness growth at a CAGR of 14.9% during the forecast period, with a market size of USD 11.31 million in 2024.
• The Rest of Latin America's Cyclosporine Market is projected to witness growth at a CAGR of 13.7% during the forecast period, with a market size of USD 25.30 million in 2024.

Middle East and Africa Cyclosporine

According to Cognitive Market Research, the global Cyclosporine Market size was estimated at USD 3142.5 Million, out of which the Middle East and Africa held the major market share of around 2% of the global revenue with a market size of USD 62.85 million in 2024 and will grow at a compound annual growth rate (CAGR) of 14.9% from 2024 to 2031.

• The GCC Countries Cyclosporine Market is projected to witness growth at a CAGR of 15.7% during the forecast period, with a market size of USD 26.90 million in 2024. Lead in the Middle East due to significant healthcare investments and growing transplant procedures.
• The Egypt Cyclosporine Market is projected to witness growth at a CAGR of 15.2% during the forecast period, with a market size of USD 6.60 million in 2024.
• The South Africa Cyclosporine Market is projected to witness growth at a CAGR of 15.9% during the forecast period, with a market size of USD 9.93 million in 2024. Rapid expansion due to growing healthcare investments and increasing awareness of immunosuppressive therapies.
• The Turkey Cyclosporine Market is projected to witness growth at a CAGR of 14.4% during the forecast period, with a market size of USD 5.41 million in 2024.
• The Nigeria Cyclosporine Market is projected to witness growth at a CAGR of 14.0% during the forecast period, with a market size of USD 6.60 million in 2024.
• The Rest of the MEA Cyclosporine Market is projected to witness growth at a CAGR of 13.9% during the forecast period, with a market size of USD 7.42 million in 2024.

Cyclosporine Market Analysis

How are Segments Performing in the Global Cyclosporine Market?

Cyclosporine Market Route of Administration Segment Analysis

According to Cognitive Market Research, the oral route of administration is the dominant category in the Cyclosporine market, as it is the most commonly prescribed form for both transplant patients and those with autoimmune diseases. Oral Cyclosporine is convenient for long-term treatment, offering patients an easier and more comfortable option for daily medication.

The injectable route of administration is the fastest-growing category in the Cyclosporine market. Injectable formulations are increasingly preferred in hospital settings, particularly for patients who require immediate and controlled doses, such as post-transplant recipients or those with severe autoimmune conditions. The growing use of injectables in critical care is driving this segment's growth.

The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Cyclosporine Industry. Request a Free Sample PDF!

Cyclosporine Market Indication Segment Analysis

According to Cognitive Market Research, the dominant category in the Cyclosporine market is Transplant Rejection Prophylaxis, as it is widely used to prevent organ rejection following kidney, liver, and heart transplants. Cyclosporine is a critical immunosuppressive drug for transplant patients, making this indication the largest contributor to market demand. The growing number of transplant surgeries and the need for effective rejection prevention therapies continue to drive this category's dominance.

The fastest-growing category is Psoriasis, driven by an increasing prevalence of this chronic autoimmune condition and the rising adoption of Cyclosporine as an effective treatment. With the growing focus on managing psoriasis symptoms and improving patients' quality of life, the demand for Cyclosporine in this indication is rapidly expanding, particularly in regions with high rates of autoimmune disorders.

The above Graph is for representation purposes only. This chart does not depict actual Market share.

Cyclosporine End User Outlook: Segment Analysis

Cyclosporine Market End User Segment Analysis

According to Cognitive Market Research, Hospitals are the dominant end-user category in the Cyclosporine market due to the high volume of organ transplant surgeries and the need for specialized treatment of autoimmune diseases. Hospitals provide the necessary infrastructure for administering Cyclosporine through both oral and intravenous formulations, making them the primary setting for initial treatments and post-transplant care. They also offer comprehensive monitoring and medical support, essential for patients on long-term immunosuppressive therapy.

Homecare is the fastest-growing segment, driven by the increasing trend of patients seeking more convenient and cost-effective treatment options. With advancements in telemedicine and the availability of oral Cyclosporine formulations, patients can manage their treatments at home, reducing hospital visits. This trend is expected to continue as healthcare systems focus on enhancing patient comfort and lowering treatment costs.

• Hospitals
• Homecare
• Speciality Centres
• Others

Author's Detail

Manjiri Kanhere

Senior Research Associate at Cognitive Market Research

LinkedIn

Profile

Manjiri Kanhere is an experienced market researcher focused on the Pharma & Healthcare industry. With over 3+ years of experience, She has worked with major pharmaceutical companies and healthcare providers, helping them to understand market trends, identify new business opportunities, and develop effective sales & marketing strategies. Her expertise lies in the ability to analyze complex data sets and deliver insights that drive business decisions. At Cognitive Market Research, she handles the market research related to Pharma and healthcare industry.

Author's Conclusion